Efficiency of topical bacterial lysates in inflammatory diseases of the oral cavity and pharynx

Abstract

Acute and chronic infectious and inflammatory diseases of the upper respiratory tract occupy one of the leading places in the structure of morbidity of the population of the world and remain the most frequent cause of patients seeking medical care. The prevalence and frequency of respiratory infectious diseases make a significant contribution to the structure of the causes of temporary disability, which entails negative socio-economic consequences. Specific attention in the current epidemic season is attracted by the change in the traditional structure of pathogens associated with several strict anti-epidemic measures during the COVID-19 pandemic, as well as a decrease in the activity of other pathogens during the active circulation of SARS-CoV-2. In this aspect, the increased resistance of pathogens to etiotropic drugs and insufficiency of the arsenal of pathogenic drugs dictate the need to search for alternative approaches to the treatment of inflammatory diseases of the mouth and throat. The main purpose of non-specific preventive measures of acute and recurrent diseases of the oral cavity and pharynx is to reduce bacterial content of mucous membranes by various pathogens and to activate own protective anti-infective mechanisms. In clinical practice medicines which contain bacterial lysates are considered to be an effective part of treatment of upper respiratory tract’s inflammatory diseases. They allow achieving elimination of a pathogenic organism and also help to restore autoregulation of immune response in the whole organism, reduce the frequency of infectious diseases. Topical bacterial lysates, acting directly in the locus of inflammation, do not harm the human microbiome, have a high safety profile, combine well with other medicines and can be used for patients of different ages. Topical immunotherapy has a significant preventive effect, preventing possible complications and improving the quality of life. The use of Imudon and IRS 19 leads to positive clinical and immunological shifts and promotes the efficiency of rehabilitation and preventive measures.